blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2266549

EP2266549 - METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION [Right-click to bookmark this link]
Former [2010/52]Method of making particles for use in a pharmaceutical composition
[2019/12]
StatusPatent revoked
Status updated on  15.07.2022
Database last updated on 06.07.2024
FormerThe patent has been granted
Status updated on  05.07.2019
FormerGrant of patent is intended
Status updated on  26.06.2019
FormerExamination is in progress
Status updated on  17.06.2019
FormerGrant of patent is intended
Status updated on  18.02.2019
FormerExamination is in progress
Status updated on  10.01.2017
Most recent event   Tooltip15.07.2022Revocation of patentpublished on 17.08.2022  [2022/33]
Applicant(s)For all designated states
Vectura Limited
1 Prospect West
Chippenham, Wiltshire SN14 6FH / GB
[2019/32]
Former [2010/52]For all designated states
Vectura Limited
1 Prospect West
Chippenham, Wiltshire SN14 6FH / GB
Inventor(s)01 / STANIFORTH, John Nicholas
Vectura Limited
High Trees Bloomfield Road
Bath, Bath and North East Somerset BA2 2ST / GB
02 / MORTON, David Alexander Vodden
Vectura Limited
2nd Floor Flat Linsley House
Beechen Cliff Road
Bath, Bath and North East Somerset BA2 4QR / GB
03 / MUSA, Rosella
Chiesi Farmaceutici SpA
Chiesi Farmaceutici SpA
Via Palermo 26/Q
43100 Parma / IT
 [2019/12]
Former [2010/52]01 / Staniforth, John, Nicholas
Vectura Limited High Trees Bloomfield Road
Bath, Bath and North East Somerset BA2 2ST / GB
02 / Morton, David, Alexander, Vodden
Vectura Limited 2nd Floor Flat Linsley House Beechen Cliff Road
Bath, Bath and North East Somerset BA2 4QR / GB
03 / Musa, Rosella
Chiesi Farmaceutici SpA Chiesi Farmaceutici SpA Via Palermo 26/Q
I-43100, Parma / IT
Representative(s)Summersell, Richard John, et al
Vectura Limited
205 Cambridge Science Park
Milton Road
Cambridge CB4 0GZ / GB
[2019/32]
Former [2010/52]McNamara, Kathryn, et al
Venner Shipley LLP Byron House Cambridge Business Park Cowley Road
Cambridge CB4 0WZ / GB
Application number, filing date10185471.927.06.2001
[2010/52]
Priority number, dateGB2000002926330.11.2000         Original published format: GB 0029263
EP2000011360827.06.2000         Original published format: EP 00113608
WO2001GB0173217.04.2001         Original published format: PCT/GB01/01732
[2010/52]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2266549
Date:29.12.2010
Language:EN
[2010/52]
Type: A3 Search report 
No.:EP2266549
Date:18.01.2012
Language:EN
[2012/03]
Type: B1 Patent specification 
No.:EP2266549
Date:07.08.2019
Language:EN
[2019/32]
Search report(s)(Supplementary) European search report - dispatched on:EP16.12.2011
ClassificationIPC:A61K9/72, A61K9/14
[2010/52]
CPC:
A61K9/0075 (EP,US); A61K9/14 (KR); A61K9/1688 (US);
A61K31/137 (EP,US); A61K31/167 (EP,US); A61K31/4468 (EP,US);
A61K31/4985 (EP,US); A61K31/573 (EP,US); A61K31/58 (EP,US);
A61K9/145 (EP,US); A61K9/1617 (US); A61K9/1623 (US);
A61P11/06 (EP) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2017/41]
Former [2010/52]AT,  BE,  CH,  CY,  DE,  DK,  ES,  FI,  FR,  GB,  GR,  IE,  IT,  LI,  LU,  MC,  NL,  PT,  SE,  TR 
TitleGerman:Verfahren zur Herstellung von Partikeln zur Verwendung in einer pharmazeutischen Zusammensetzung[2019/30]
English:METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION[2019/12]
French:Procedé permettant de produire des particules destinées à être utilisées dans une composition pharmaceutique[2019/30]
Former [2010/52]Verfahren zur Herstellung von Partikeln zur Verwendung in einer pharmazeutischen Zusammensetzung
Former [2010/52]Method of making particles for use in a pharmaceutical composition
Former [2010/52]Procedé permettant de produire des particules destinées à être utilisées dans une composition pharmaceutique
Examination procedure17.07.2012Amendment by applicant (claims and/or description)
17.07.2012Examination requested  [2012/34]
01.09.2016Despatch of a communication from the examining division (Time limit: M06)
10.03.2017Reply to a communication from the examining division
07.09.2017Despatch of a communication from the examining division (Time limit: M06)
19.03.2018Reply to a communication from the examining division
03.07.2018Despatch of a communication from the examining division (Time limit: M04)
12.11.2018Reply to a communication from the examining division
19.02.2019Communication of intention to grant the patent
14.06.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
14.06.2019Fee for grant paid
14.06.2019Fee for publishing/printing paid
26.06.2019Information about intention to grant a patent
26.06.2019Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP01947612.6  / EP1296651
EP07120591.8  / EP1913939
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20010947612) is  12.05.2003
Opposition(s)Opponent(s)01  06.05.2020  19.05.2020  ADMISSIBLE
Glaxo Group Limited
980 Great West Road
Brentford Middlesex TW8 9GS / GB
Opponent's representative
J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
 [N/P]
Former [2020/39]
Opponent(s)01  06.05.2020  19.05.2020  ADMISSIBLE
Glaxo Group Limited
980 Great West Road
Brentford Middlesex TW8 9GS / GB
Opponent's representative
J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2020/25]
Opponent(s)01  06.05.2020    ADMISSIBLE
Glaxo Group Limited
980 Great West Road
Brentford Middlesex TW8 9GS / GB
Opponent's representative
Sardharwala, Fatema Elyasali
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
17.06.2020Invitation to proprietor to file observations on the notice of opposition
28.10.2020Reply of patent proprietor to notice(s) of opposition
21.02.2022Cancellation of oral proceeding that was planned for 24.02.2022
24.02.2022Date of oral proceedings
31.03.2022Despatch of communication that the patent will be revoked
10.04.2022Legal effect of revocation of patent [2022/33]
Fees paidRenewal fee
24.01.2011Renewal fee patent year 03
24.01.2011Renewal fee patent year 04
24.01.2011Renewal fee patent year 05
24.01.2011Renewal fee patent year 06
24.01.2011Renewal fee patent year 07
24.01.2011Renewal fee patent year 08
24.01.2011Renewal fee patent year 09
24.01.2011Renewal fee patent year 10
28.06.2011Renewal fee patent year 11
29.03.2012Renewal fee patent year 12
25.06.2013Renewal fee patent year 13
31.03.2014Renewal fee patent year 14
29.06.2015Renewal fee patent year 15
27.06.2016Renewal fee patent year 16
27.06.2017Renewal fee patent year 17
29.10.2018Renewal fee patent year 18
27.06.2019Renewal fee patent year 19
Penalty fee
Additional fee for renewal fee
30.06.201818   M06   Fee paid on   29.10.2018
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT07.08.2019
CY07.08.2019
DK07.08.2019
ES07.08.2019
FI07.08.2019
IT07.08.2019
MC07.08.2019
NL07.08.2019
SE07.08.2019
TR07.08.2019
GR08.11.2019
PT09.12.2019
LU27.06.2020
BE30.06.2020
GB26.06.2021
IE27.06.2021
[2022/27]
Former [2021/46]AT07.08.2019
DK07.08.2019
ES07.08.2019
FI07.08.2019
IT07.08.2019
MC07.08.2019
NL07.08.2019
SE07.08.2019
TR07.08.2019
GR08.11.2019
PT09.12.2019
LU27.06.2020
BE30.06.2020
GB26.06.2021
IE27.06.2021
Former [2021/38]AT07.08.2019
DK07.08.2019
ES07.08.2019
FI07.08.2019
IT07.08.2019
MC07.08.2019
NL07.08.2019
SE07.08.2019
TR07.08.2019
GR08.11.2019
PT09.12.2019
LU27.06.2020
BE30.06.2020
GB26.06.2021
Former [2021/24]AT07.08.2019
DK07.08.2019
ES07.08.2019
FI07.08.2019
IT07.08.2019
MC07.08.2019
NL07.08.2019
SE07.08.2019
TR07.08.2019
GR08.11.2019
PT09.12.2019
LU27.06.2020
BE30.06.2020
Former [2021/15]AT07.08.2019
DK07.08.2019
ES07.08.2019
FI07.08.2019
IT07.08.2019
MC07.08.2019
NL07.08.2019
SE07.08.2019
TR07.08.2019
GR08.11.2019
PT09.12.2019
LU27.06.2020
Former [2021/12]AT07.08.2019
DK07.08.2019
ES07.08.2019
FI07.08.2019
IT07.08.2019
MC07.08.2019
NL07.08.2019
SE07.08.2019
TR07.08.2019
GR08.11.2019
PT09.12.2019
Former [2020/23]AT07.08.2019
DK07.08.2019
ES07.08.2019
FI07.08.2019
IT07.08.2019
NL07.08.2019
SE07.08.2019
TR07.08.2019
GR08.11.2019
PT09.12.2019
Former [2020/22]DK07.08.2019
ES07.08.2019
FI07.08.2019
NL07.08.2019
SE07.08.2019
TR07.08.2019
GR08.11.2019
PT09.12.2019
Former [2020/17]ES07.08.2019
FI07.08.2019
NL07.08.2019
SE07.08.2019
TR07.08.2019
GR08.11.2019
PT09.12.2019
Former [2020/12]ES07.08.2019
FI07.08.2019
NL07.08.2019
SE07.08.2019
GR08.11.2019
PT09.12.2019
Former [2020/10]FI07.08.2019
NL07.08.2019
SE07.08.2019
PT09.12.2019
Former [2020/09]FI07.08.2019
NL07.08.2019
Documents cited:Search[X]WO8705213  (CHIESI FARMA SPA [IT]) [X] 10,12-15 * examples 1A,2 *;
 [X]EP0260241  (DRACO AB [SE]) [X] 1-3,7,10-12,14,15 * examples 1,7 *;
 [XD]WO9623485  (CO ORDINATED DRUG DEV [GB], et al) [XD] 1-15 * page 23, line 23 - page 25, line 14 * * examples 3-13 * * figures 4A,4B *;
 [X]WO9831346  (MASSACHUSETTS INST TECHNOLOGY [US], et al) [X] 10-15 * page 39, line 26 - page 40, line 6 * * example 5 *;
 [X]WO0028979  (SKYEPHARMA AG [CH], et al) [X] 10-12,14,15 * page 15, line 30 - line 32 * * examples 1-6 *;
 [X]WO0033789  (R P SCHERER INC [US], et al) [X] 10-12,14,15 * page 4, line 4 - line 7 * * page 6, line 7 - line 10 * * example - *;
 [X]WO0033811  (VECTURA LTD [GB], et al) [X] 10-15 * example 5 *;
 [E]WO0178693  (CHIESI FARMA SPA [IT], et al) [E] 1-4,6-12,14,15 * claim - ** examples 1-3,7D,7E,8,9 *
by applicantUS4349542
 WO9623485
 WO9723485
    - A. E. HAWKINS, The Shape of Powder-Particle Outlines, WILEY
    - J. PHARM. PHARMACOL, (1987), vol. 39, pages 966 - 972
OppositionGB1381872
 WO9623485
 WO0053158
 WO0178693
 EP2283817
    - Anonymous, "formoterol fumarate", British National Formulary, (20200429), pages 1 - 4, XP055762002
    - Anonymous, "Formoterol. Compound Summary", PubChem, (20200429), pages 1 - 2, XP055762003
    - NUHA KASSEM, thesis submitted to Kings College, (19900000), XP002687372
    - L. S. DUBROVINSKY ET AL., "The hardest known oxide", Nature, London, (20010405), vol. 410, doi:10.1038/35070650, ISSN 0028-0836, pages 653 - 654, XP002379183

DOI:   http://dx.doi.org/10.1038/35070650
    - Göran Alderborn, Nyström, Christer, "Pharmaceutical Powder Compaction Technology. Excerpt", Marcel Dekker, (19960101), pages 292 - 299, XP055761993
    - Joseph I. Goldstein, "Scanning Electron Microscopy & X-Ray Microanalysis. Excerpt Chapter 24", Springer, (20170101), pages 414 - 417, XP055761987
    - Joseph I. Goldstein, "Scanning Electron Microscopy & X-Ray Microanalysis. Excerpt Chapter 10", Springer, (20030101), pages 491 - 492, XP055761989
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.